Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by João Raposo.
Journal of Clinical Oncology | 2008
Robert Marcus; Kevin Imrie; Philippe Solal-Celigny; John Catalano; Anna Dmoszynska; João Raposo; Fritz Offner; José Gomez-Codina; Andrew R. Belch; David Cunningham; Elisabeth Wassner-Fritsch; George Stein
PURPOSE To compare the long-term outcome of patients with previously untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide, vincristine and prednisone (CVP) versus CVP plus rituximab (R-CVP) and to evaluate the predictive value of known prognostic factors after treatment with R-CVP. PATIENTS AND METHODS Patients with previously untreated CD20-positive stage III/IV FL were randomly assigned to eight cycles of R-CVP (n = 159) or CVP alone (n = 162). The median follow-up period was 53 months. RESULTS The primary end point-time to treatment failure (TTF), which included patients without a response after four cycles as an event-was significantly prolonged in patients receiving R-CVP versus CVP (P < .0001). Improvements in all other end points, including overall and complete response rates (P < .0001), time to progression (TTP; P < .0001), response duration (P < .0001), time to next antilymphoma treatment (P < .0001), and overall survival (OS; P = .029; 4-year OS: 83% v 77%;) were achieved with R-CVP versus CVP alone. Univariate analyses demonstrated an improvement in TTP with R-CVP versus CVP irrespective of the Follicular Lymphoma International Prognostic Index (FLIPI) subgroup, the International Prognostic Index (IPI) subgroup, baseline histology, and the presence or absence of B symptoms or bulky disease. By multivariate analysis, FLIPI retains a strong predictive power for TTP in the presence of the trial treatment effect. CONCLUSION Analysis of all outcome measures, including OS, confirm the benefit of adding R to CVP in the front-line treatment of FL.
Blood | 2015
Fritz Offner; Olga Samoilova; Evgenii Osmanov; Hyeon-Seok Eom; Max S. Topp; João Raposo; Viacheslav Pavlov; Deborah Ricci; Shalini Chaturvedi; Eugene Zhu; Helgi van de Velde; Christopher Enny; Aleksandra Rizo; Burhan Ferhanoglu
This phase 2 study evaluated whether substituting bortezomib for vincristine in frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy could improve efficacy in non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL), centrally confirmed by immunohistochemistry (Hans method). In total, 164 patients were randomized 1:1 to receive six 21-day cycles of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2), and doxorubicin 50 mg/m(2), all IV day 1, prednisone 100 mg/m(2) orally days 1-5, plus either bortezomib 1.3 mg/m(2) IV days 1, 4, 8, 11 (rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib [VR-CAP]; n = 84) or vincristine 1.4 mg/m(2) (maximum 2 mg) IV day 1 (R-CHOP; n = 80). There were no significant differences between VR-CAP and R-CHOP in complete response rate (64.5%, 66.2%; odds ratio [OR], 0.91; P = .80), overall response rate (93.4%, 98.6%; OR, 0.21; P = .11), progression-free survival (hazard ratio [HR], 1.12; P = .76), or overall survival (HR, 0.89; P = .75). Rates of grade ≥3 adverse events (AEs; 88%, 89%), serious AEs (38%, 34%), discontinuations due to AEs (7%, 3%), and deaths due to AEs (2%, 5%) were similar with VR-CAP and R-CHOP. Grade ≥3 peripheral neuropathy rates were 6% and 3%, respectively. VR-CAP did not improve efficacy vs R-CHOP in non-GCB DLBCL. This trial was registered at www.clinicaltrials.gov as #NCT01040871.
Haematologica | 2018
Anne-Sophie Michallet; Melih Aktan; Wolfgang Hiddemann; Osman Ilhan; Peter Johansson; Kamel Laribi; Balkis Meddeb; Carol Moreno; João Raposo; Anna Schuh; Ali Unal; Tom Widenius; Alf Bernhardt; Kerstin Kellershohn; Dimitri Messeri; Stuart Osborne; Véronique Leblond
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia. Patients received rituximab plus bendamustine or rituximab plus chlorambucil every four weeks for six cycles. Rituximab plus chlorambucil-treated patients without a complete response after Cycle 6 received chlorambucil monotherapy for at least six additional cycles or until complete response. The primary endpoint was complete response rate (confirmed by bone marrow biopsy) after Cycle 6 in first-line patients. Secondary endpoints included progression-free survival, overall survival, minimal residual disease, and safety. Overall, 357 patients were randomized (rituximab plus bendamustine, n=178; rituximab plus chlorambucil, n=179; intent-to-treat population), including 241 first-line patients (n=121 and n=120, respectively); 355 patients received treatment (n=177 and n=178, respectively; safety population). In first-line patients, complete response rate after Cycle 6 (rituximab plus bendamustine, 24%; rituximab plus chlorambucil, 9%; P=0.002) and median progression-free survival (rituximab plus bendamustine, 40 months; rituximab plus chlorambucil, 30 months; P=0.003) were higher with rituximab plus bendamustine than rituximab plus chlorambucil. Overall response rate and overall survival were not different. In first-line patients with a complete response, minimal residual disease-negativity was higher with rituximab plus bendamustine than rituximab plus chlorambucil (66% vs. 36%). Overall adverse event incidence was similar (rituximab plus bendamustine, 98%; rituximab plus chlorambucil, 97%). Rituximab plus bendamustine may be a valuable first-line option for fludarabine-ineligible patients with chronic lymphocytic leukemia.
Haematologica | 2018
Véronique Leblond; Melih Aktan; Christelle M Ferra Coll; Caroline Dartigeas; Jens Kisro; Marco Montillo; João Raposo; Jean-Louis Merot; Susan Robson; Ekaterina Gresko; Francesc Bosch; Stephan Stilgenbauer; Robin Foà
The safety of obinutuzumab, alone or with chemotherapy, was studied in a non-randomized, open-label, non-comparative, phase IIIb study (GREEN) in previously untreated or relapsed/refractory chronic lymphocytic leukemia. Patients received obinutuzumab 1000 mg alone or with chemotherapy (investigator’s choice of fludarabine-cyclophosphamide for fit patients, chlorambucil for unfit patients, or bendamustine for any patient) on days 1, 8 and 15 of cycle 1, and day 1 of cycles 2–6 (28-day cycles), with the cycle 1/day 1 dose administered over two days. The primary end point was safety/tolerability. Between October 2013 and March 2016, 972 patients were enrolled and 971 treated (126 with obinutuzumab monotherapy, 193 with obinutuzumab-fludarabine-cyclophosphamide, 114 with obinutuzumab-chlorambucil, and 538 with obinutuzumab-bendamustine). Grade ≥3 adverse events occurred in 80.3% of patients, and included neutropenia (49.9%), thrombocytopenia (16.4%), anemia (9.6%), and pneumonia (9.0%); rates were similar in first-line and relapsed/refractory patients, and in first-line fit and unfit patients. Using expanded definitions, infusion-related reactions were observed in 65.4% of patients (grade ≥3, 19.9%; mainly seen during the first obinutuzumab infusion), tumor lysis syndrome in 6.4% [clinical and laboratory; highest incidence with obinutuzumab-bendamustine (9.3%)], and infections in 53.7% (grade ≥3, 20.1%). Serious and fatal adverse events were seen in 53.1% and 7.3% of patients, respectively. In first-line patients, overall response rates at three months post treatment exceeded 80% for all obinutuzumab-chemotherapy combinations. In the largest trial of obinutuzumab to date, toxicities were generally manageable in this broad patient population. Safety data were consistent with previous reports, and response rates were high. (clinicaltrials.gov identifier: 01905943).
Critical Reviews in Oncology Hematology | 2012
C. Viveiros; M. Neves; C. Ferreira; Sofia Santos; S. Matos; João Raposo; J. Alves do Carmo
OR20 Lenalidomide in 5q− syndrome? An efficient therapeutic option C. Viveiros1 *, M. Neves1, C. Ferreira2, S. Santos3, S. Matos3, J. Raposo1, J. Alves do Carmo1. 1Centro Hospitalar Lisboa Norte − Hospital Santa Maria, EPE, Department of Hematologia, Lisbon, Portugal, 2Centro Hospitalar Lisboa Norte − Hospital Santa Maria, EPE, Department of Servico de Anatomia Patologica, Lisbon, Portugal, 3Genomed − Diagnosticos de Medicina Molecular − Instituto de Medicina Molecular, Department of Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
Blood | 2005
Robert Marcus; Kevin Imrie; Andrew R. Belch; David Cunningham; Eduardo Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; João Raposo; Andrew Jack; Paul Smith
Blood | 2003
Robert Marcus; Kevin Imrie; Andrew R. Belch; David Cunningham; E Flores; John Catalano; Philippe Solal-Celigny; Fritz Offner; Jan Walewski; João Raposo; Andrew Jack; Paul Smith
Blood | 2006
Robert Marcus; Philippe Solal-Celigny; Kevin Imrie; John Catalano; Anna Dmoszynska; João Raposo; Fritz Offner; José Gomez-Codina
Blood | 2012
Véronique Leblond; Kamel Laribi; Osman Ilhan; Melih Aktan; Ali Unal; Saad M. B. Rassam; Anna Schuh; Tom Widenius; Peter Johansson; João Raposo; Balkis Meddeb; Carol Moreno; Stephan Oertel; Anne-Sophie Michallet
Blood | 2005
Philippe Solal-Celigny; Kevin Imrie; Andrew R. Belch; Katherine Sue Robinson; David Cunningham; Antonio Rueda; John Catalano; Fritz Offner; Jan Walewski; João Raposo; Paul Smith; Robert Marcus